From Stem to Sternum: The Role of Shp2 in the Skeleton

被引:2
作者
Jensen, Nathaniel R. [1 ]
Kelly, Ryan R. [2 ,3 ]
Kelly, Kirsten D. [2 ]
Khoo, Stephanie K. [2 ]
Sidles, Sara J. [2 ,3 ]
LaRue, Amanda C. [2 ,3 ]
机构
[1] Washington Univ, Dept Pediat, St Louis, MO 63130 USA
[2] Ralph H Johnson VA Hlth Care Syst, Res Serv, Charleston, SC 29401 USA
[3] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA
关键词
SHP2; Bone; SHP099; Skeleton; Development; PROTEIN-TYROSINE-PHOSPHATASE; AMPA RECEPTOR TRAFFICKING; NOONAN-SYNDROME; LEOPARD-SYNDROME; PTPN11; MUTATIONS; PHOSPHOTYROSINE PHOSPHATASE; OSTEOBLAST DIFFERENTIATION; GROWTH; ACTIVATION; CELLS;
D O I
10.1007/s00223-022-01042-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Src homology-2 domain-containing phosphatase 2 (SHP2) is a ubiquitously expressed phosphatase that is vital for skeletal development and maintenance of chondrocytes, osteoblasts, and osteoclasts. Study of SHP2 function in small animal models has led to insights in phenotypes observed in SHP2-mutant human disease, such as Noonan syndrome. In recent years, allosteric SHP2 inhibitors have been developed to specifically target the protein in neoplastic processes. These inhibitors are highly specific and have great potential for disease modulation in cancer and other pathologies, including bone disorders. In this review, we discuss the importance of SHP2 and related signaling pathways (e.g., Ras/MEK/ERK, JAK/STAT, PI3K/Akt) in skeletal development. We review rodent models of pathologic processes caused by germline mutations that activate SHP2 enzymatic activity, with a focus on the skeletal phenotype seen in these patients. Finally, we discuss SHP2 inhibitors in development and their potential for disease modulation in these genetic diseases, particularly as it relates to the skeleton.
引用
收藏
页码:403 / 421
页数:19
相关论文
共 151 条
[1]   A WIDELY EXPRESSED HUMAN PROTEIN-TYROSINE PHOSPHATASE CONTAINING SRC HOMOLOGY-2 DOMAINS [J].
AHMAD, S ;
BANVILLE, D ;
ZHAO, ZZ ;
FISCHER, EH ;
SHEN, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (06) :2197-2201
[2]   The generalized bone phenotype in children with neurofibromatosis 1: A sibling matched case-control study [J].
Armstrong, Linlea ;
Jett, Kimberly ;
Birch, Patricia ;
Kendler, David L. ;
McKay, Heather ;
Tsang, Erica ;
Stevenson, David A. ;
Hanley, David A. ;
Egeli, Deetria ;
Burrows, Melonie ;
Friedman, J. M. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (07) :1654-1661
[3]   Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations [J].
Bauler, Timothy J. ;
Kamiya, Nobuhiro ;
Lapinski, Philip E. ;
Langewisch, Eric ;
Mishina, Yuji ;
Wilkinson, John E. ;
Feng, Gen-Sheng ;
King, Philip D. .
DISEASE MODELS & MECHANISMS, 2011, 4 (02) :228-U112
[4]   PROTEIN-TYROSINE-PHOSPHATASE SHPTP2 COUPLES PLATELET-DERIVED GROWTH-FACTOR RECEPTOR-BETA TO RAS [J].
BENNETT, AM ;
TANG, TL ;
SUGIMOTO, S ;
WALSH, CT ;
NEEL, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (15) :7335-7339
[5]   Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia [J].
Bentires-Alj, M ;
Paez, JG ;
David, FS ;
Keilhack, H ;
Halmos, B ;
Naoki, K ;
Maris, JM ;
Richardson, A ;
Bardelli, A ;
Sugarbaker, DJ ;
Richards, WG ;
Du, JY ;
Girard, L ;
Minna, JD ;
Loh, ML ;
Fisher, DE ;
Velculescu, VE ;
Vogelstein, B ;
Meyerson, M ;
Sellers, WR ;
Neel, BG .
CANCER RESEARCH, 2004, 64 (24) :8816-8820
[6]   PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome [J].
Binder, G ;
Neuer, K ;
Ranke, MB ;
Wittekindt, NE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09) :5377-5381
[7]   SHP2 Regulates Chondrocyte Terminal Differentiation, Growth Plate Architecture and Skeletal Cell Fates [J].
Bowen, Margot E. ;
Ayturk, Ugur M. ;
Kurek, Kyle C. ;
Yang, Wentian ;
Warman, Matthew L. .
PLOS GENETICS, 2014, 10 (05)
[8]   Loss-of-Function Mutations in PTPN11 Cause Metachondromatosis, but Not Ollier Disease or Maffucci Syndrome [J].
Bowen, Margot E. ;
Boyden, Eric D. ;
Holm, Ingrid A. ;
Campos-Xavier, Belinda ;
Bonafe, Luisa ;
Superti-Furga, Andrea ;
Ikegawa, Shiro ;
Cormier-Daire, Valerie ;
Bovee, Judith V. ;
Pansuriya, Twinkal C. ;
de Sousa, Sergio B. ;
Savarirayan, Ravi ;
Andreucci, Elena ;
Vikkula, Miikka ;
Garavelli, Livia ;
Pottinger, Caroline ;
Ogino, Toshihiko ;
Sakai, Akinori ;
Regazzoni, Bianca M. ;
Wuyts, Wim ;
Sangiorgi, Luca ;
Pedrini, Elena ;
Zhu, Mei ;
Kozakewich, Harry P. ;
Kasser, James R. ;
Seidman, Jon G. ;
Kurek, Kyle C. ;
Warman, Matthew L. .
PLOS GENETICS, 2011, 7 (04)
[9]   Hematopoietic Colony Formation from Human Growth Factor-Dependent TF1 Cells and Human Cord Blood Myeloid Progenitor Cells Depends on SHP2 Phosphatase Function [J].
Broxmeyer, Hal E. ;
Etienne-Julan, Maryse ;
Gotoh, Akihiko ;
Braun, Stephen E. ;
Lu, Li ;
Cooper, Scott ;
Feng, Gen-Sheng ;
Li, Xing Jun ;
Chan, Rebecca J. .
STEM CELLS AND DEVELOPMENT, 2013, 22 (06) :998-1006
[10]   Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis [J].
Bunda, Severa ;
Burrell, Kelly ;
Heir, Pardeep ;
Zeng, Lifan ;
Alamsahebpour, Amir ;
Kano, Yoshihito ;
Raught, Brian ;
Zhang, Zhong-Yin ;
Zadeh, Gelareh ;
Ohh, Michael .
NATURE COMMUNICATIONS, 2015, 6